Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Invested Capital (2020 - 2025)

Historic Invested Capital for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $724.7 million.

  • Maravai Lifesciences Holdings' Invested Capital fell 3611.9% to $724.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $724.7 million, marking a year-over-year decrease of 3611.9%. This contributed to the annual value of $873.1 million for FY2024, which is 3355.25% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Invested Capital is $724.7 million, which was down 3611.9% from $761.9 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Invested Capital's 5-year high stood at $1.4 billion during Q4 2022, with a 5-year trough of $724.7 million in Q3 2025.
  • For the 5-year period, Maravai Lifesciences Holdings' Invested Capital averaged around $1.1 billion, with its median value being $1.2 billion (2022).
  • In the last 5 years, Maravai Lifesciences Holdings' Invested Capital surged by 5931.16% in 2022 and then tumbled by 4116.96% in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Invested Capital (Quarter) stood at $1.1 billion in 2021, then surged by 33.15% to $1.4 billion in 2022, then dropped by 8.28% to $1.3 billion in 2023, then crashed by 33.55% to $873.1 million in 2024, then fell by 17.0% to $724.7 million in 2025.
  • Its Invested Capital stands at $724.7 million for Q3 2025, versus $761.9 million for Q2 2025 and $825.2 million for Q1 2025.